Stockscreener 앱 받기
14.24
4.02%
0.55
시간 외 거래:
14.21
-0.03
-0.21%
전일 마감가:
$13.69
열려 있는:
$13.88
하루 거래량:
137.89K
Relative Volume:
1.55
시가총액:
$190.19M
수익:
$6.67M
순이익/손실:
$-47.55M
주가수익비율:
-9.4933
EPS:
-1.5
순현금흐름:
$-17.44M
1주 성능:
-1.11%
1개월 성능:
+22.76%
6개월 성능:
+2,685%
1년 성능:
+2,685%
1일 변동 폭
$13.71
$14.49
1주일 범위
$12.96
$14.74
52주 변동 폭
$10.83
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
명칭
Crescent Biopharma Inc
전화
617-430-5595
주소
300 FIFTH AVENUE, WALTHAM, CA
CBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
14.24 | 190.19M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 개시 | Jefferies | Buy |
| 2025-08-11 | 개시 | H.C. Wainwright | Buy |
| 2025-07-14 | 개시 | Wedbush | Outperform |
| 2025-06-25 | 개시 | Stifel | Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma to Present at September Investor Conferences - AInvest
Crescent Biopharma (NASDAQ:CBIO) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cancer Drug Developer Crescent Biopharma to Present at Major September Healthcare Conferences - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Given Buy Rating at HC Wainwright - Defense World
Stifel reiterates Buy rating on Crescent Biopharma stock at $28 target - Investing.com
Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - AInvest
This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies Initiates Coverage of Crescent Biopharma with Buy Rating and $26 Price Target - AInvest
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating By Investing.com - Investing.com Nigeria
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating - Investing.com
Crescent Biopharma shares rise 3.70% intraday after Pyxis Oncology CEO to participate in September investor conferences. - AInvest
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma: Chasing The Summit Hype - Seeking Alpha
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $25.50 Consensus Target Price from Analysts - Defense World
Q3 Earnings Forecast for CBIO Issued By HC Wainwright - Defense World
HC Wainwright Initiates Coverage on Crescent Biopharma (NASDAQ:CBIO) - Defense World
Crescent Biopharma Initiated with Buy Rating and $25 Price Target by H.C. Wainwright - AInvest
Analysts Initiate Coverage on Arm Holdings with Bullish Predictions - AInvest
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Benzinga
Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27 - 富途牛牛
Crescent Biopharma (NASDAQ:CBIO) Cut to “Sell” at Wall Street Zen - Defense World
Crescent Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crescent Biopharma: Q2 Earnings Snapshot - Greenwich Time
Crescent Biopharma Advances Cancer Therapeutics with CR-001 and ADCs, Completes Merger and Nasdaq Listing - AInvest
Crescent Biopharma's Promising Pipeline and Strategic Positioning Support Buy Rating - AInvest
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
CRESCENT BIOPHARMA, INC. SEC 10-Q Report - TradingView
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Upgraded by Wall Street Zen - Defense World
What is Wedbush’s Estimate for CBIO Q2 Earnings? - Defense World
Wedbush Begins Coverage on Crescent Biopharma (NASDAQ:CBIO) - Defense World
Wedbush Initiates Crescent Biopharma at Outperform With $27 Price Target - MarketScreener
Wedbush Initiates Coverage of Crescent Biopharma (CBIO) with Outperform Recommendation - MSN
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Wall Street Zen to Sell Rating - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Galectin Therapeutics shares rise 3.30% premarket after Crescent Biopharma appoints new Chief Scientific Officer. - AInvest
Crescent Biopharma Snatches Oncology Star Jan Pinkas—Here's Why This Could Be a Game-Changer - AInvest
Crescent Biopharma appoints Jan Pinkas as chief scientific officer - Investing.com
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer - GlobeNewswire
ADC Pioneer with ELAHERE Success Record Joins Crescent Biopharma as Chief Scientific Officer - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200 Day Moving Average – Should You Sell? - Defense World
Why Did Crescent Biopharma Drop 10.72%? - AInvest
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Crescent Biopharma: A Promising Investment in the Growing PD-(L)1-Targeting Market - TipRanks
Crescent Biopharma (CBIO) Receives a New Rating from TD Cowen - The Globe and Mail
Petri Dish: Turkish firm backs Harvard lab, Isomorphic opens in Cambridge - The Business Journals
Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks
Crescent Biopharma Inc (CBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):